Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2024

Oh Hyung-Joo, Bae Suk-Chul, Oh In-Jae, Park Cheol-Kyu, Jung Kyoung-Mi, Kim Da-Mi, Lee Jung-Won, Kang Chang Kyun, Park Il Yeong, Kim Young-Chul

Abstract excerpt

PURPOSE: RUNX3 is a tumor suppressor gene, which is inactivated in approximately 70% of lung adenocarcinomas. Nicotinamide, a sirtuin inhibitor, has demonstrated potential in re-activating epigenetically silenced RUNX3 in cancer cells. This study assessed the therapeutic benefits of combining nicotinamide with first-generation EGFR-tyrosine kinase inhibitors (TKI) for patients with stage IV lung cancer carrying...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Niacinamide

Share to Prognosis

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 38593249
DOI: 10.1158/1078-0432.CCR-23-3059

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.PMID 38593249Read ↗

Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic ProspectsSemantic proximity Read ↗

Pan-cancer analysis combined with experiments predicts NNMT as a therapeutic target for human cancersSemantic proximity Read ↗

RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.Semantic proximity Read ↗

Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment.Semantic proximity Read ↗

AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality.Semantic proximity Read ↗

Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cellsSemantic proximity Read ↗

Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status.Semantic proximity Read ↗

Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer TherapySemantic proximity Read ↗

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT InhibitorsSemantic proximity Read ↗

Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up studySemantic proximity Read ↗

Association between Retinoic acid receptor-β hypermethylation and NSCLC risk: a meta-analysis and literature review.Semantic proximity Read ↗

NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.